You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Augmentin logo

Product menu

Amoxicillin-clavulanate: Proven efficacy in community-acquired bacterial infections
Pack-shot

Choose the confidence of Augmentin, your reliable partner in tackling common community-acquired bacterial infections.

11
13
14
16
42
52

Need help with this product?

Request a contact

Stay Informed

Request a rep

Augmentin safety information12

Contraindications

AUGMENTIN is contra-indicated in patients with a history of hypersensitivity to beta-lactams, e.g. penicillins and cephalosporins

AUGMENTIN is contra-indicated in patients with a previous history of AUGMENTIN-associated jaundice/hepatic dysfunction. 

Warnings and precautions

Serious and occasionally fatal hypersensitivity (anaphylactoid) reactions have been reported in patients on penicillin therapy. These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity

Adverse Events

Very Common: Diarrhoea (in adults)
Common: nausea, vomiting, mucocutaneous candidiasis, diarrhoea (in children)

References

  1. Dagan R and Leibovitz E. Lancet Infect Dis. 2002;2(10):593–604.
  2. Data on file. Augmentin ES GDS Version 24. June 2019.
  3. Data on File: Augmentin ES–600 Phase IV Study. REF-196810.
  4. White AR, et al. J Antimicrob Chemother. 2004;53(Suppl 1):i3–20.
  5. Hoberman A, et al. Pediatr Infect Dis J. 2005;24(6):525–32.
  6. Survey of Antibiotic Resistance (SOAR) results: respiratory pathogen susceptibility. J Antimicrob Chemother. 2016;71(Suppl1):i3–i19.
  7. Haczyński J, et al. Med Sci Monit. 2001;7(5):1016–22.
  8. Asensi F, et al. Rev Esp Quimioter 1999;12(3):211214.
  9.  Lin T-Y, et al. Chang Gung Med J. 2007;30(4):321–32.
  10. Postma DF, et al. N Engl J Med. 2015;372(14):1312–23.
  11. Liu S, et al. Front Pharmacol. 2019;10:489.
  12. Augmentin prescribing information.

 

3rd party links not owned or controlled by GSK.

For more information, please refer to the prescribing information or contact GlaxoSmithKline via gcc.medinfo@gsk.com
To report Adverse Event/s associated with the use of GSK product/s, please contact us via
gulf.safety@gsk.com
To report quality complaint/s associated with the use of GSK product/s, please contact us via
 Gulf.ProductQualityComplaints@gsk.com

Department of Pharmacovigilance & Drug Information
Directorate General of Pharmaceutical Affairs & Drug Control
Ministry of Health, Sultanate of Oman
Phone Nos. 0096822357687 / 0096822357686
Fax: 0096822358489
Email: pharma-vigil@moh.gov.om
Website: www.moh.gov.om

 دائرة التيقظ و المعلومات الدوائية
المديرية العامة للصيدلة و الرقابة الدوائية
وزارة الصحة, سلطنة عمان
0096822357687 / 0096822357686 :هاتف
0096822358489 :فاكس
pharma-vigil@moh.gov.om :البريد الالكتروني
www.moh.gov.om :الموقع الالكتروني

Trademarks are owned by or licensed to the GSK group of companies.
©2024 GSK group of companies or its licensor. All rights reserved. 

PM-RCH-ACA-WCNT-240003 Date of preparation: July 2024